N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

This study is testing a treatment approach for children with high-risk neuroblastoma (a type of cancer that develops in nerve tissue, most often in young children) that uses reduced chemotherapy combined with targeted antibody therapy, aiming to achieve good results with fewer side effects. **You may be eligible if...** - Your child has been diagnosed with neuroblastoma (confirmed by biopsy, bone marrow, or imaging) - Your child has high-risk neuroblastoma with MYCN gene amplification or is older than 18 months with stage M disease - Your child has received no more than one prior cycle of high-risk neuroblastoma chemotherapy **You may NOT be eligible if...** - Your child has already received extensive chemotherapy for this condition - Your child has another serious illness that would prevent treatment - The cancer does not meet the high-risk criteria defined in the study Talk to your doctor to see if this trial is right for you.